Adequate tacrolimus concentration for myasthenia gravis treatment.

Journal: European journal of neurology
PMID: 28102047

Abstract

BACKGROUND AND PURPOSE: A single, oral dose of 3 mg/day tacrolimus, approved for myasthenia gravis (MG) treatment in Japan, was shown to reduce steroid dose and anti-acetylcholine receptor (AChR) antibody titers as well as to improve MG symptoms. However, no studies have investigated the association between tacrolimus concentration and its clinical efficacy in MG. In this study, we aimed to determine the optimal tacrolimus concentration for MG treatment.

Authors

  • T Kanai
    Department of Neurology, Graduate School of Medicine, Chiba University, Chiba.
  • A Uzawa
    Department of Neurology, Graduate School of Medicine, Chiba University, Chiba.
  • N Kawaguchi
    Department of Neurology, Graduate School of Medicine, Chiba University, Chiba.
  • K Himuro
    Department of Neurology, Graduate School of Medicine, Chiba University, Chiba.
  • F Oda
    Department of Neurology, Graduate School of Medicine, Chiba University, Chiba.
  • Y Ozawa
    Department of Neurology, Graduate School of Medicine, Chiba University, Chiba.
  • S Kuwabara
    Department of Neurology, Graduate School of Medicine, Chiba University, Chiba.

Keywords

External Resources

Popular Topics
Recent Journals